Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,067 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 399
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Type 1 Diabetes132
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections105
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California498
- Maryland198
- Alabama178
- Florida151
- Arizona150
- Massachusetts118
- New York114
- Texas112
- Illinois84
- Colorado81
Recruiting studies6,067 total
- NCT05300451Enrolling by invitationPhase 2
Daratumumab to help lower rejection risk before heart transplant
This Phase 2 trial tests daratumumab to reduce your body’s immune reaction (HLA antibodies) before a heart or heart-and-kidney transplant. It may help lower the risk of immediate, severe rejection in people who already have high antibody levels.
Rochester, MinnesotaAges 18–80 - NCT05288790RecruitingPhase 2
Study how gut chemicals and alcohol affect heart risk in HIV
This Phase 2 study looks at how “microbiome metabolites” (chemicals from gut bacteria) and alcohol may affect heart and blood vessel risk in people living with HIV. If you qualify, you may be asked to follow a study plan to see how these factors change health markers related to cardiovascular disease.
Nashville, TennesseeAges 18–89 - NCT05268250Recruiting
Program to help school families cope with type 1 diabetes stress
This trial tests a structured program and screening approach to help school-age children and their families who are feeling significant stress about diabetes. It may help by identifying distress early and offering targeted support alongside an intensive diabetes care plan.
Jacksonville, FloridaAges 8–65 - NCT05289167RecruitingPhase 1/Phase 2
Medicines to prevent graft-versus-host disease after a transplant
This trial tests a combination of medicines (post-transplant cyclophosphamide, bortezomib, and abatacept) to lower your chance of developing graft-versus-host disease (when transplanted immune cells attack your body) after a transplant. If you qualify, you’ll receive the study medicines as part of your post-transplant care and be followed closely to check safety and prevention of GvHD.
New Hyde Park, New YorkAges 14–100 - NCT05260957RecruitingPhase 2
CAR-T, mosunetuzumab, and polatuzumab for hard-to-treat lymphoma
This Phase 2 trial tests a combination approach to treat certain aggressive, relapsed, or refractory non-Hodgkin lymphomas. It may help by using CAR-T cells (a patient-specific immune treatment) along with other lymphoma medicines to shrink or control the cancer.
Miami, FloridaAges 18–80 - NCT05258396Recruiting
Remyelination study for teens with multiple sclerosis
This study tests whether the brain may “repair” itself (re-myelinate) in children and teens with multiple sclerosis. It uses brain MRI to look for changes and may help clinicians better understand how to treat MS in younger people.
Le Kremlin-BicêtreAges 12–18 - NCT05265273RecruitingPhase 2/Phase 3
Nipocalimab for children with generalized myasthenia gravis
This trial studies nipocalimab, an immune-focused medicine, to see if it can improve generalized myasthenia gravis (gMG) in children ages 2 to under 18. It may help reduce weakness caused by this autoimmune muscle disease, but you must meet specific antibody and health requirements.
Phoenix, ArizonaAges 2–17 - NCT05302934Recruiting
Testing a knee-surgery app and sensor after knee replacement
This trial checks whether a data platform that uses a wearable sensor and a phone app works well for people getting a total knee replacement. It may help make follow-up care more organized and easier by capturing recovery information.
Konstanz, Baden-WurttembergAges 18 years+ - NCT05303519RecruitingPhase 3
Safusidenib for IDH1-mutant glioma after main treatment
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
Birmingham, AlabamaAges 18 years+ - NCT04573673Recruiting
Tapping the shin nerve to help bladder control in MS
This study tests a noninvasive nerve stimulation applied to the lower leg to improve bladder emptying problems in people with multiple sclerosis. It may help reduce bladder dysfunction while you keep using clean intermittent self-catheterization.
LilleAges 18–65 - NCT04826744Recruiting
Atopic dermatitis study tracking eyelid involvement
This study looks at how often the eyelids are affected in adults with atopic dermatitis (a long-term skin condition). It may help doctors better understand patterns of skin and eyelid symptoms so care can be improved.
LilleAges 18 years+ - NCT05243797RecruitingPhase 3
Teclistamab plus lenalidomide maintenance after transplant
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
Phoenix, ArizonaAges 18 years+ - NCT05201469RecruitingPhase 2
VIB4920 for lupus kidney inflammation not responding well enough
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
La Jolla, CaliforniaAges 18 years+ - NCT05237986Recruiting
Study brain and thinking effects after CAR T therapy in youth
This study looks at how CAR T-cell treatment affects thinking, learning, and day-to-day brain function in children and young adults with certain blood cancers. You (and a caregiver) may complete online testing so researchers can track these changes over time and whether support is needed.
Los Angeles, CaliforniaAges 5 years+ - NCT05248659Enrolling by invitationPhase 2/Phase 3
Sibeprenlimab for IgA kidney disease after prior study
This trial studies sibeprenlimab to see if it can improve IgA nephropathy, a kidney inflammation condition. You may be able to join if you finished a previous related Otsuka study without major safety problems and your doctor thinks you could benefit.
Birmingham, AlabamaAges 18 years+ - NCT05201781RecruitingPhase 4
Long-term follow-up for people previously treated with cilta-cel
This study follows people over time who previously received cilta-cel in a Janssen-sponsored clinical trial. It helps doctors learn about how well the treatment works and how safe it is in the long run.
Phoenix, ArizonaAges 18 years+ - NCT05199688RecruitingPhase 3
Satralizumab for children with AQP4-positive NMOSD attacks
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
Denver, ColoradoAges 2–11 - NCT05254743RecruitingPhase 3
Pirtobrutinib versus ibrutinib for CLL or SLL
This Phase 3 trial compares two oral medicines—pirtobrutinib and ibrutinib—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who need treatment. It’s designed to see which drug works better and is easier to take, especially for people with a specific genetic change in the cancer (17p deletion).
Anaheim, CaliforniaAges 18 years+ - NCT05222529RecruitingPhase 2
Study medicine dosing in children with asthma using inhaler tests
This Phase 2 study checks how glycopyrronium bromide works in children with asthma, including its safety and how well inhaler dosing is tolerated. It also uses breathing tests and inhaler technique checks to confirm your child meets key asthma and lung function requirements.
RousseAges 6–11 - NCT05256641RecruitingPhase 1/Phase 2
Acalabrutinib maintenance after transplant or CAR T for large B-cell lymphoma
This trial studies acalabrutinib given after certain lymphoma treatments (like stem cell transplant or CAR T therapy) to help keep the lymphoma from coming back. It’s for people whose disease has shrunk (partial response) or fully gone away (complete response) after those treatments.
Los Angeles, CaliforniaAges 18–70 - NCT05229432Recruiting
Oatmeal meal test to study stomach movement in eosinophilic gastritis
This study looks at how your stomach moves (gastric motility) in people with eosinophilic gastritis, using a special oatmeal meal. The goal is to better understand stomach function and how it may relate to symptoms.
Chicago, IllinoisAges 18–59 - NCT05199532Recruiting
Eosinophilic gut condition registry for children
This study builds a registry of children with eosinophilic gastrointestinal (gut) disorders (EGIDs) and also includes children being evaluated for possible EGIDs. It may help doctors better understand these conditions and improve future care.
Chicago, IllinoisAges 1–25 - NCT05235633Enrolling by invitation
Daily activities after cancer treatment in children
This study looks at how children and teens manage everyday activities like dressing, eating, and moving around right after finishing treatment for leukemia or lymphoma. It aims to understand their needs and help improve recovery support.
MunichAges 4–18 - NCT05208307RecruitingPhase 2
Belantamab with pomalidomide and dexamethasone after high-risk myeloma transplant
This Phase 2 study tests a treatment combination (belantamab mafodotin, pomalidomide, and dexamethasone) for high-risk multiple myeloma after an autologous stem cell transplant. It aims to improve disease control in people who have certain genetic features or aggressive disease behavior.
Atlanta, GeorgiaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,067 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,241 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.